Roivant Sciences Ltd
F:87S
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Roivant Sciences Ltd
Balance Sheet
Balance Sheet Decomposition
Roivant Sciences Ltd
| Current Assets | 6.7B |
| Cash & Short-Term Investments | 6.5B |
| Receivables | 82.8m |
| Other Current Assets | 113.3m |
| Non-Current Assets | 490.7m |
| Long-Term Investments | 247.8m |
| PP&E | 66m |
| Intangibles | 137.8m |
| Other Non-Current Assets | 39.1m |
| Current Liabilities | 266.8m |
| Accounts Payable | 53.2m |
| Accrued Liabilities | 185.5m |
| Other Current Liabilities | 28.1m |
| Non-Current Liabilities | 987.1m |
| Long-Term Debt | 430.6m |
| Other Non-Current Liabilities | 556.6m |
Balance Sheet
Roivant Sciences Ltd
| Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
2 183
|
2 055
|
2 060
|
1 677
|
6 536
|
|
| Cash Equivalents |
2 183
|
2 055
|
2 060
|
1 677
|
6 536
|
|
| Total Receivables |
15
|
14
|
0
|
33
|
83
|
|
| Accounts Receivables |
9
|
11
|
0
|
30
|
54
|
|
| Other Receivables |
7
|
3
|
0
|
2
|
29
|
|
| Inventory |
0
|
0
|
0
|
3
|
35
|
|
| Other Current Assets |
21
|
118
|
86
|
86
|
78
|
|
| Total Current Assets |
2 219
|
2 187
|
2 147
|
1 799
|
6 732
|
|
| PP&E Net |
74
|
77
|
87
|
92
|
66
|
|
| Intangible Assets |
0
|
0
|
0
|
145
|
138
|
|
| Long-Term Investments |
93
|
290
|
326
|
304
|
248
|
|
| Other Long-Term Assets |
90
|
36
|
26
|
50
|
39
|
|
| Total Assets |
2 477
N/A
|
2 590
+5%
|
2 585
0%
|
2 390
-8%
|
7 222
+202%
|
|
| Liabilities | ||||||
| Accounts Payable |
10
|
21
|
35
|
38
|
53
|
|
| Accrued Liabilities |
77
|
89
|
139
|
179
|
185
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
43
|
12
|
|
| Other Current Liabilities |
5
|
109
|
11
|
13
|
16
|
|
| Total Current Liabilities |
92
|
219
|
184
|
272
|
267
|
|
| Long-Term Debt |
109
|
170
|
210
|
379
|
431
|
|
| Minority Interest |
77
|
264
|
405
|
450
|
480
|
|
| Other Liabilities |
168
|
138
|
129
|
131
|
77
|
|
| Total Liabilities |
445
N/A
|
792
+78%
|
928
+17%
|
1 232
+33%
|
1 254
+2%
|
|
| Equity | ||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1 109
|
1 919
|
2 764
|
3 773
|
576
|
|
| Additional Paid In Capital |
3 144
|
3 815
|
4 422
|
4 933
|
5 396
|
|
| Other Equity |
2
|
99
|
1
|
3
|
4
|
|
| Total Equity |
2 032
N/A
|
1 798
-12%
|
1 657
-8%
|
1 158
-30%
|
5 969
+416%
|
|
| Total Liabilities & Equity |
2 477
N/A
|
2 590
+5%
|
2 585
0%
|
2 390
-8%
|
7 222
+202%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
685
|
685
|
695
|
760
|
807
|
|
You don't have any saved screeners yet
